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IFN-y is a lymphokine synthesized and secreted by stimulated T lymphocytes.
One of the important functions of IFN--y is the activation of mononuclear
phagocytes so that they are capable of killing a wide spectrum of intracellular
pathogens (reviewed in reference 1). This process requires from 24 to 48 h and
is associated with the enhanced production of reactive oxygen intermediates, a
finding that may be explained by the greater affinity of the membrane oxidase
for NADPH (2). More recently we have found that IFN-y rapidly induces the
expression of genes in macrophages and other cell types (3). One of these genes
has been sequenced and codes for a 10-kD secreted protein (IP-10) with signifi-
cant homology to a family of chemotactic and mitogenic proteins, including the
a-platelet granule proteins platelet factor 4 (PF4)' and 0-thromboglobulin (OTG).
The preparation of a polyclonal rabbit antibody against recombinant IP-10 (4)
has now allowed us to examine the in situ formation of this protein in human
tissues. For this purpose we have used a number of human conditions in which
delayed-type hypersensitivity is either expressed or not expressed in the skin.
For the former, we have used a classic purified protein derivative of tuberculin
(PPD) reaction as well as the response to rIFN-y injected into the skin (5-7). In
addition, the polar forms of leprosy reflect a more chronic state in which
tuberculoid lesions contain all the components of a delayed-type hypersensitivity
(DTH) reaction, whereas lepromatous lesions lack the important helper T cell
phenotype (8). Using immunocytochemistry we have now followed the temporal
expression of two IFN-y induced molecules, HLA DR (Ia) and IP-10, during
immune response in the cells of the human dermis and epidermis.
Materials and Methods
The Generation of a DTH Response to PPD.
￿
After informed consent, we evaluated the
delayed response to 5 U of PPD in 65 lepromatous leprosy patients from New Delhi,
India (a high endemic area for tuberculosis). The study group included 45 lepromatous
(LL) and 20 borderline lepromatous leprosy patients (BL) (9). The leprosy patients were
examined in collaboration with Drs. A . K. Sharma and R. S. Mishra, at the Department
of Dermatology, Safdarjung Hospital, New Delhi. Clinical diagnosis was accompanied by
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'Abbreviations used in this paper.
￿
aMEM, a-modified Eagle's medium; OTG, 0-thromboglobulin ;
HUVE, human umbilical cord endothelial cells; PF4, platelet factor 4; PPD, purified protein
derivativeof tuberculin.
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a histopathological diagnosis established by Dr. 1. Nath of the Department of Pathology
All India Institute of Medical Sciences, New Delhi. Antigen was injected intradermally
into the skin of the back . Two 4-mm punch biopsies, one from the PPD-injected site and
one from an uninjected adjacent site, were taken at 18, 41, 68-72, and 96 h, and at 1
and 2 wk after injection from lepromatous and borderline lepromatous patients. The
biopsies were fixed as described below and transported to the United States for further
processing.
Leprosy Patients.
￿
After informed consent, skin biopsies from 10 untreated patients
from Brazil with various forms of leprosy were collected and examined. The Brazilian
patients were examined in collaboration with Dr. E. N. Sarno of the Department of
General Pathology, Hospital de Clinicas, Universidade do Estado do Rio de Janeiro.
Clinical diagnosis was accompanied by a histopathological diagnosis established by Dr. E.
N . Sarno according to the RidleyJopling classification (9).
Fixation and Processing of Cutaneous Biopsies.
￿
Skin biopsies were fixed in paraformal-
dehyde (3%), lysine (0.075 M), and sodium-m-periodate (0 .01 M) in PBS for 4 h at 4°C
as described by McLean and Nakane (10-11). The biopsies were incubated in PBS
containing sucrose (10%) and digitonin (0.05 mM) and then serially suspended in graded
solutions of sucrose (15-25%). The biopsies were stored in PBS with sucrose/glycerol (25
and 5%, respectively) until frozen .
Immunocytochemical Staining of Sections.
￿
The biopsies were embedded in OCT com-
pound and frozen at -20°C. 6-8-um sections were cut on a cryostat and applied to gelatin
coated multiwell slides (Carlson Scientific Inc., Peotene, IL). The sections were dried
overnight at 37'C, rehydrated in PBS and incubated with mouse mAbs or rabbit anti-rIP-
10 antibodies followed by biotinylated horse anti-mouse Ig or goat anti-rabbit Ig and
then avidin-biotin peroxidase complexes (Vector Laboratories, Inc ., Burlington, CA). The
reaction product was developed with 0.8 mg/ml 3-amino-9-ethylcarbazole in 0.02 M Tris
buffer, pH 7 .6, and 0 .015 H202. The controls for IP-10 binding were: (a) normal rabbit
serum, (b) absence of primary antibody and (c) antiserum against the 22-amino-acid
COOH-terminal peptide of IP-10, which does not precipitate the intact molecule from
induced cells (4). The controls for mAbs included the omission of the primary antibody.
None of the controls gave any staining (see figures). Sections were counterstained with
hematoxylin.
Monoclonal Antibodies.
￿
Mouse anti-human mAbs were used for the identification of
specific cell types. OKT6 (anti-thymocyte and Langerhans' cells) was obtained from Ortho
Diagnostics Systems Inc. (Raritan, NJ) (12). 9.3F10 (anti-HLA class II) was produced in
this laboratory (13). The cell line 63D3 (anti-monocyte/macrophage) was obtained from
American Type Culture Collection (Rockville, MD) (14). Leu-1 (anti-pan-T lymphocyte),
Leu-2a (anti-suppressor/cytotoxic T lymphocyte), and Leu-3a (anti-helper T lymphocyte)
were obtained from Becton Dickinson Monoclonal Centers, Inc. (Mountain View, CA)
(15-16). Adjacent sections were evaluated for specific cell staining with a Nikon Micro-
phot-FX light microscope.
Cell Culture. A primary keratinocyte cell line isolated from human foreskin was
obtained from Clonetics Corporation (Boulder, CO) and maintained in a defined kerati-
nocyte growth medium (17). Experiments were carried out on fourth-passage cells. The
human fibroblast cell line FS4 was grown in a-modified Eagle's medium (aMEM) with
10% FCS and antibiotics. Human endothelial cellswere isolated from umbilical cord veins
(18) and grown in M 199 medium supplemented with 20% heat-inactivated human serum,
penicillin (100 U/ml), and streptomycin (100 ug/ml). All the experiments were performed
on second-passage human umbilical cord endothelial cells (HUVE). PBMC were isolated
from venous blood fractionated on a Ficoll-Hypaque gradient. Monocytes were isolated
from these PBMC by Percoll gradient fractionation (19) and maintained in aMEM
supplemented with 10% heat-inactivated autologous human serum or FCS, penicillin, and
streptomycin.
All induction experiments were performed in the regular cell growth medium, using
cells just before reaching confluence. Monocytes were induced at 106 cells/ml. The IFN-1100
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y was always diluted into medium containing 10% serum, except for keratinocytes where
serum was omitted.
-y-Interferon.
￿
The IFN used in in vitro studies was highly purified recombinant protein
synthesized in Escherichia coli generously provided by Genentech, Inc ., So. San Francisco,
CA. The endotoxin levels were determined in a Limulus amoebocyte lysate assay before
shipping. The human rIFN-y had a specific activity of 2-4 X 10' U/mg as determined in
a human lung carcinoma A549 inhibition assay using the encephalomyocarditis virus. The
lyophilized excipient and rIFN-y (sp act, 2 X 10' U/mg protein) used in in vivo studies
were obtained from Genentech, Inc., and diluted to a final concentration of 100,ug/ml.
Immunoprecipitation.
￿
Cells were lysed in PBS containing 1 % NP-40, 0.2 U/ml apro-
tinin, I mM PMSF,and 0.1 % diisopropylfluorophosphate (Sigma Chemical Co., St. Louis,
MO) and prepared for immunoprecipitation as described (4). Affinity-purified antibodies
were added to clarified cell lysates and cell supernatants to a final concentration of 0.5
Ag/ml. The solution was incubated at room temperature for 4-16 h. Antigen-antibody
complexes were precipitated by incubation with protein A-Sepharose, washed in buffer
and detergent solution, and released from the beads by incubation at 100°C for 2 min in
2x PAGE sample buffer. 15% SDS-PAGE gels were run as described in the legend to
Fig. 3. The densitometric scan (Spectrophotometer; Beckman Instruments, Inc., Fuller-
ton, CA) was done on an autoradiogram exposed for 42 h for keratinocytes, 3 d for
endothelial cells, 6 d for monocytes, and 3 wk for fibroblasts. These exposure times were
selected to scan gels that were in the linear range of the x-ray exposures. Relative density
units were calculated from the computerized area below the peak multiplied by the length
ofexposure of the gels in hours and standardized to I U for fibroblasts.
Results
A rabbit polyclonal antiserum raised against the IFN-y-induced protein IP-10
(4) has been used in this study to demonstrate the expression of the peptide in
DTH responses of human skin. Since the peptide is first expressed in the basal
layer of the epidermis, the immunoperoxidase reaction was developed with 3-
amino-9-ethylcarbazole, which gives a red stain easily distinguished from the
brown color of melanin granules.
Staining of Normal Skin and Skin from the Lesions of Lepromatous Leprosy
Patients. When normal human skin was examined for the expression of IP-10
and la antigen, no staining of the keratinocytes or any of the dermal macro-
phages, fibroblasts, or endothelial cells was observed. T6+ Langerhans' cells of
the epidermis, which express la antigen constitutively, did not stain for IP-10
(not shown) .
Examination of biopsies from the skin lesions of lepromatous leprosy patients
revealed a dermal accumulation of parasitized macrophages, often with a very
foamy appearance, and a few lymphocytes. These cells expressed la antigen as
did the T6' Langerhans' cells of the epidermis (Fig. 2A). However, no staining
for IP-10 was observed in the cells of the dermis or the epidermis (Fig. 1 A).
The DTH Response to PPD Injection.
￿
The intradermal injection of 5 U of PPD
in previously sensitized lepromatous patients provided us with an excellent model
for the study of delayed immune responses in humans. Temporal examination
of the reaction site revealed a local accumulation of T lymphocytes and mono-
cytes (Kaplan, G., A. Nusrat, S. Laal, et al., manuscript in preparation). A
majority of the T cells that infiltrated the reaction site were of the OKT4/Leu-
3a subset.
Staining of tissue sections of biopsies taken from 18 h to 2 wk after PPD
injection enabled us to analyze the kinetics and persistence of expression of bothKAPLAN ET AL.
￿
1101
IP-10 and la antigen. In the dermis the induction of low levels of IP-10 was
observed in scattered monocytes, fibroblasts, and endothelial cells by 18 h and
even more prominantly by 41 h after PPD injection (Fig. 1). Staining persisted
for at least 1 wk and usually subsided completely by 2 wk. The in vivo expression
of IP-10 in these cells confirmed in vitro studies showing the induction of IP-10
after exposure of monocytes and endothelial cells to rIFN-y (4, 6). la antigen, a
molecule known to be induced by IFN-y, was also expressed by 18 h on the
newly infiltrating cells in the dermis.
Striking results were observed in the epidermis. By 18 h after the injection of
PPD, single cells in the basal layer ofthe epidermis were clearly staining for IP-
10 (Fig. 1B). At 41 h all the cells of the basal layer were stained (Fig. 1 C). With
time, stained cells were observed higher up in the epidermis until by about 1 wk
all the keratinocytes were staining (Fig. ID). The expression of Ia antigen
paralleled the results for IP-10. At 18 h, fewer basal keratinocytes stained for la
than for IP-10 (Fig. 2B). By 41 h many of the keratinocytes were Ia+ (Fig. 2C)
and by 72 h to 1 wk the entire epidermis was positive (Fig. 2D). Staining for la
antigen usually subsided by 2 wk (not shown).
The staining ofthe keratinocytes for IP-10 appeared much more intense than
the staining of the cells in the dermis. While the staining for IP-10 was clearly in
the cytoplasm of the cells, la antigen was membrane associated. The changes in
antigen expression were clearly restricted to the site of the DTH response.
The Response to Intradermal Injection of rIFN-y.
￿
We have previously reported
(7) that intradermal injection of low doses of rIFN-y into the lesions of lepro-
matous leprosy patients mimics the DTH responses to antigen. In our present
studies we have examined the effect ofa single injection of 10 JAg of rIFN-'y on
the expression ofIP-10 and Ia antigen. The local response to such treatment has
generally been lower in intensity and duration than the response to 5 U ofPPD.
Intradermal administration of the excipient had no effect on the cellular
composition or phenotype of the cells (Figs. 1 E and 2E compared to Figs. 1 A
and 2A). Neither IP-10 nor Ia antigens were expressed. However, a single
injection of 10 jug of rIFN-y induced the expression ofIP-10 in the basal cells of
the epidermis by 18 h (not shown) in a similar way to that observed with PPD.
Very little if any IP-10 was observed in the dermal cells at this time. By 72 h
many of the basal keratinocytes stained for IP-10 but in most patients the cells
ofthe upper epidermis were not stained (Fig. 1 F). IP-10 expression persisted in
some cells for up to 4-5 d and was reduced or totally absent from most cells by
6-7 d. In some patients that gave a larger reaction to intradermal rIFN-y (30-
40 mm of induration) the IP-10 expression was more intense and persisted for
at least 7 d, more like the response to PPD.
The expression of la antigen was also induced by intradermal injection of 10
AgofrIFN-y but not by excipient alone (Fig. 2, E and F). By 18 h after injection
a few patches of keratinocytes of the basal layer of the epidermis were Ia' (not
shown). At 41 h extensive staining was observed andby 72 h the entire epidermis
was often Ia+ (Fig. 2F). la antigen expression persisted for at least 1 wK and had
disappeared by 2-3 wk. In general, the staining for Ia appeared somewhat later
than thatobserved for IP-10, but by 41 h it was more intense, appeared on more
cells of the epidermis and dermis, and persisted for longer.FIGURE 1 .
￿
Immunohistochemical localization of IP-10 in human skin . (A) The skin of a
lepromatous leprosy patient stained for IP-10 . No red stain is seen in the dermis or the
epidermis. (B-D) Thedelayed immune response to intradermal injection of PPD in leproma-
tous leprosy patients . (B) IS h after administration of antigen, individual cells of basal layer of
the epidermis are staining (arrows). (C) 41 h after antigen administration, all the cells of the
basal layer of the epidermis are staining . Some red stain can also be seen in association with
cells in the dermis (arrows) . (D) 7 d after administration of antigen, most of the cells of the
epidermis and some of the dermal cells are staining . (E) Skin lesion of lepromatous patient
injected intradermally with 100 jul excipient alone (no rIFN--Y control) and biopsied 72 h after
injection . No red stain is observed . (F) Skin lesion oflepromatous patient injected intradermally
with 10 lug rIFN-f in 10 Al of excipientand biopsied 72 h later . Some of the cells of the basal
layer of the epidermis are staining. (H-G) Lesion of untreated tuberculoid leprosy patient
stained for IP-10. (G) the cells of the epidermis and the dermis are intensely stained . (H) no
primary antibody control, no red stain is observed . Magnifications : A-F, X 320 ; G-H, x 200.FIGURE 2 .
￿
Immunohistochemical localization of la antigen in human skin . (A) The skin of a
lepromatous leprosy patient stained for la antigen . The cells of the dermis are all staining for
la antigen . The Langerhans' cells are the only cells staining in the epidermis, no stain is seen
on the keratinocytes . (B-D)Thedelayedimmune response to intradermal injection ofPPD in
lepromatous leprosy patients . (B) 18 h after administration of antigen, the cells of the dermis
are staining andthe majority ofthe cells of the basal layer of the epidermis are not yet staining .
(C) 41 h after antigen administration, almost all the cells of the epidermis are staining. (D) 7
d after administration ofantigen, most ofthe cells ofthe epidermisand the dermis are staining .
(E) Skin lesion of lepromatous patient injected intradermally with 100 uI excipient alone (no
rIFN--y control) and biopsied 72 h after injection . No epidermal stain is observed . (F) Skin
lesion of lepromatous patient injected intradermally with 10 Ag rIFN--y in 100 A1 of excipient
and biopsied 72 h later . All the cells of the epidermis are staining . (H-G) Lesion of untreated
tuberculoid leprosy patient stained for la antigen. (G) The cells of the epidermis and the
dermis are intensely stained . (H) No primary antibody control, no stain is observed . Magnifi-
cation, x 200 .
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FIGURE 3.
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IP-10 and Ia Expression in the Lesions of Tuberculoid Leprosy and Cutaneous
Leishmaniasis. Patients with the tuberculoid form of leprosy, undergoing
chronic DTH reactions in the epidermal lesions, have large numbers of T
lymphocytes of the helper phenotype in their lesions (8) and express la antigen
on the keratinocytes overlying the lesions (5). In these patients, the infiltrating
cells of the dermis and the keratinocytes of the epidermis stained intensely for
IP-10 (Fig. I G). This staining is in keeping with continued local production of
IFN-y by dermal T cells. In contrast to tuberculoid leprosy, the lesions of
lepromatous leprosy show the absence of T helper lymphocytes and la antigen
expression on keratinocytes of the epidermis and do not express IP-10 in the
skin.
A similar observation was made when the chronic lesions ofcutaneous Leish-
maniasis were examined (not shown).
The Inducible Expression ofIP-10 in Keratinocytes In Vitro.
￿
The strong staining
reaction of keratinocytes as compared with other cell types suggested that
keratinocytes might be a major producer of IP-10. To investigate the relative
synthetic capacity of these cells we established in vitro cultures of human
keratinocytes. The secretory and protein processing patterns were evaluated in
parallel cultures of human monocytes, fibroblasts, endothelial cells, and kerati-
nocytes. The cells were either left untreated or induced with 100 U/ml ofrIFN-
y for 4 h and then biosynthetically labeled with [s5S]methionine for 10 h. The
cell lysates and supernatants were immunoprecipitated using the anti-IP-10
antibodies and were analyzed by SDS-PAGE, and the amount of IP-10 immu-
noprecipitated was quantitated by gel scanning. The four cell types examined
reveal a similar pattern of induction, secretion, and processing of the IP-10
protein (4). Keratinocytes secreted 185 density units as compared with endothe-
lial cells (67 U), monocytes (7 U), and fibroblast (1 U) (Fig. 3). All the cells
produced IP-10 only in the presence of rIFN-y. ^-94% of synthesized IP-10 was
secreted by all cell types tested.KAPLAN ET AL.
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Discussion
Our knowledge of the stimulation of helper T cells and the concordant
production of lymphokines comes largely from in vitro studies. In this milieu,
incubation ofresting T cells in the presence ofantigen and the potent accessory
cell, thedendriticcell oritsequivalent, leads to the generation ofthe macrophage
activating lymphokine IFN--y. This and other soluble products are synthesized
in proportion to the number ofsensitized T cells that undergo blastogenesis. In
the present in vivo experiments we have generated all the known components of
this reaction within the confines of the human dermis. After the introduction of
antigen into thedermis, large number ofTcells ofthe helper phenotype emigate
from the vasculature and, with monocytes, form the primary elements of the
delayed immune response. In addition, T6' Langerhans' cells, presumably from
the circulation, enter the lesion and could serve as potent accessory cells (20-
23). As a result, lymphokines are produced and influence many cells in the
dermal and epidermal environment. Our ability to monitor the production of
lymphokines depends largely upon their modulation of other cells. In the case
of IFN-y we observe the prompt and extensive expression of class II MHC
determinants on the surface of overlying keratinocytes, a process already de-
scribed in some detail (5, 24-25). We assume that dermal T cells are the source
of IFN-y and that the lymphokine diffuses from the DTH reaction inducing la
expression. Other responses to IFN-y such as macrophage activation are less easy
to observe, although the subsequent fate of intracellular Mycobacterium leprae to
an evoked DTH reaction is currently under study.
We have now carried the analysis of the delayed immune response further
through our ability to localize other molecules induced by IFN-'y. The discovery
that IFN-y induces the early expression of IP-10 allowed us to produce specific
antibodies against the molecule and subsequently to identify it in tissue sections
byimmunocytochemical means. Temporal analysis ofthe cellsand immune states
in which IP-10 is expressed form the major portion of the present manuscript.
Both monocytes, macrophages, and endothelial cells are stained for IP-10 in the
dermis after the first 24 h after administration of stimulant. Although largely a
secretory product, sufficient product accumulates within the cell body to allow
itsidentification in sections. To our surprise, the mostextensive staining occurred
in the keratinocytes of the epidermis. First observed within the replicating cells
ofthe basal layer, staining moved centripetallyasthe new keratinocytespopulated
the upper layers and matured. The intense in situ staining of keratinocytes is
consistent with in vitro immunoprecipitation studies in which keratinocytes
synthesize and secrete more IP-10 than either HUVE, monocytes, or fibroblasts.
The elucidation of the primary amino acid sequence of IP-10 (3) has allowed
acomparison toother known proteins. IP-10 is homologous to anewly emerging
family of chemotactic and mitogenic proteins associated with inflammation and
cell proliferation including PF4; connective tissue activating peptide III (CTAP
III), an unprocessed form of #TG; and a Rous sarcoma virus-induced protein,
9E3. These homologies suggest that IP-10 may share some of the functional
properties with other members of this family. PF4 is a potent chemoattractant
for both granulocytes and monocytes (26). Peptide CTAP III is a growth factor
for fibroblasts (27), and 9E3 is induced by the Rous Sarcoma virus (28). Such1106
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activities are of obvious interest in terms of the inflammatory response but
require more definitive experiments with IP-10. What is apparent, however, is
that IFN-y, the product ofthe Tcell, may through its induction of IP-10 recruit
a broad spectrum of "nonprofessional cells" involving them in the cell-mediated
response. Such recruitment ifcoupled with growth promotion and/or chemoat-
traction would magnify the immune response by means ofwhat wecould consider
a "secondary cytokine." Perhaps the large amount of keratinocyte IP-10 serves
as an autocrine growth regulator or promotes the directional flow of specific
epidermal populations such as the Langerhans' cell.
Summary
Our knowledge of the induction of new molecules by IFN-y has led to the
characterization of IP-10 and the preparation of a monospecific, polyclonal
antibody. Using this reagent we have now examined inflammatory states occur-
ring in human skin and used immunocytochemical staining for the expression of
both la and IP-10 determinants.
After evoking a delayed-type response to purified protein derivative oftuber-
culin (PPD), we noted the presence of IP-10 in dermal macrophages and
endothelial cells. Intense staining of the basal layer of epidermal keratinocytes
was prominent at 41 h, and by 1 wk the entire epidermis was staining. The
comparison of the amount of IP-10 secreted by keratinocytes vs. macrophages,
fibroblasts, and endothelial cells revealed that keratinocytes were by far the
major producers of this molecule. The expression of la occurred in conjunction
with IP-10. The injection of rIFN-y mimicked many of the features ofthe PPD
response, including the expression of both la and IP-10 by epidermal keratino-
cytes. Coexpression was also found in the natural lesions of tuberculoid leprosy
and cutaneous Leishmaniasis. However, it was absent in lepromatous leprosy, a
state where activated T lymphocytes are not present.
We suggest that the local production of IFN-y by T cells of the dermal
infiltrate induces IP-10 formation in both the dermis and epidermis. IP-10 and
la then serve as specific markers of immune IFN and its possible influence on
effector cells of the cell mediated immune response.
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Receivedfor Publication 3June 1987.
References
1. Nathan, C. F., and R. Yoshida. 1988 . Interferon--y in the inflammatory response. In
Inflammation: Basic Principles and Clinical Correlates. J. Gallin, 1. Goldstein, and R.
Synderman, editors. Raven Press, New York. 229-251 .
2. Tsunawaki, S., and C. F. Nathan . 1986 . Macrophage deactivation. Altered kinetic
properties ofsuperoxide-producingenzyme afterexposure to tumor cell-conditioned
medium.f. Fxp. Med. 164:1319.
3 . Luster, A. D.,J. C. Unkeless, andJ. V. Ravetch. 1985. -y-interferon transcriptionallyKAPLAN ET AL.
￿
110 7
regulates an early response gene containing homology to platelet proteins. Nature
(Lond.). 315:672.
4. Luster, A . D., and J. V. Ravetch. 1987. Biochemical characterization of a y inter-
feron-inducible cytokine (IP-10). J. Exp. Med. 166 :1084.
5. Kaplan, G., M. D. Witmer, I . Nath, R. M. Steinman, S. Laal, H. K. Prasad, E. N.
Sarno, U. Elvers, and Z. A. Cohn. 1986. Influence of delayed immune reactions on
human epidermal keratinocytes. Proc. Natl. Acad. Sci. USA. 83:3469 .
6. Nathan, C. F., G. Kaplan, W. R. Levis, A. Nusrat, M. D. Witmer, S. A . Sherwin, C.
K. Job, C. R. Horowitz, R. M. Steinman, and Z. A. Cohn. 1986. Local and systemic
effects of low doses ofrecombinant interferon--y after intradermal injection in patients
with lepromatous leprosy. N. Engl. J. Med. 315:6.
7. Kaplan, G., A. Nusrat, E. N . Sarno, C. K. Job, J. McElrath, J. A. Porto, C. F. Nathan,
and Z. A. Cohn . 1987. Cellular responses to the intradermal injection ofrecombinant
human interferon-y in lepromatous leprosy patients. Am. J. Pathol. 128:345.
8. Van Voorhis, W. C., G. Kaplan, E. N . Sarno, M. A. Horwitz, R. M . Steinman, W. R.
Levis, N . Nogueira, L. R. Hair, C. R. Gattas, B. A. Arrick, and Z. A. Cohn . 1982.
The cutaneous infiltrates of leprosy. Cellular characteristics and the predominant T-
cell phenotypes. N. Engl. J. Med. 307 :1593.
9 . Ridley, D., and W. Jopling. 1966. Classification of leprosy according to immunity: a
five-group system . Int. J. Lepr. 34:255.
10 . McLean, I . W., and P. K. Nakane. 1974. Periodate-lysine-paraformaldehyde fixative
for immunoelectron microscopy. J. Histochem. Cytochem. 22 :1077.
11 . Collings, L. A., L . W. Poulter, and G. Janossy. 1984. The demonstration of cell
surface antigens on T cells, B cells and accessory cells in parafin-embedded human
tissues. J. Immunol. Methods. 75:227.
12 . Fithian, E., P. King, G. Goldstein, M . Rubenfeld, C. Fenoglio, and R. Edelson. 1981 .
Reactivity of Langerhans' cells with hybridoma antibody. Proc. Natl. Acad. Sci. USA.
78 :2541 .
13 . Van Voorhis, W. C., R. Steinman, L. Hair, J. Luban, M. Witmer, and Z. Cohn. 1983 .
Specific mononuclear phagocyte monoclonal antibodies. Application to the purifica-
tion of dendritic cells and the tissue localization ofmacrophages.J. Exp. Med. 158:126.
14 . Ugolini, V., G. Nunez, R . G. Smith, P. Stastny, and J. D. Capra. 1980 . Initial
characterization of monoclonal antibodies against human monocytes. Proc. Natl.
Acad. Sci. USA. 77:6764.
15 . Engleman, E. G ., R. Warnke, R. I. Fox, and R. Levy. 1981 . Studies of a human T
lymphocyte antigen recognized by a monoclonal antibody. Proc. Natl. Acad. Sci. USA.
78 :1791 .
16. Evans, R. L., D. W. Wall, C. D. Platsoucas, F. P. Siegal, S. M. Fikrig, C . M. Testa,
and R. A. Good. 1981 . Thymus-dependent membrane antigens in man: inhibition of
cell mediated lympholysis by monoclonal antibodies to the TH2 antigen. Proc. Natl.
Acad. Sci. USA. 78:544.
17 . Tsao, M . C., B. J. Walthall, and R. C. Ham. 1982. Clonal growth of normal human
epidermal keratinocytes in a defined medium. J. Cell. Physiol. 110 :219.
18 . Jaffe, E. A., R. C. Nachman, C. G. Becker, and C. R. Minick. 1973 . Culture of
human endothelial cells derived from umbilical veins. Identification by morphologic
and immunologic criteria. J. Clin. Invest. 52 :2745.
19 . Wright, S. D., and S. C. Silverstein. 1982. Tumor-promoting phorbol esters stimulate
C3b and C3b' receptor-mediated phagocytosis in cultured human monocytes. J. Exp.
Med. 156:1149.
20 . Kaplan, G., A. Nusrat, M. D. Witmer, 1 . Nath, and Z. A. Cohn. 1987 . Distribution1108
￿
EXPRESSION OF IP-10 IN DELAYED IMMUNE RESPONSES
and turnover of Langerhans' cells during delayed immune responses in human skin.
J. Exp. Med. 165:763.
21 . Schuler, G., and R. M. Steinman. 1985. Murine epidermal Langerhans' cells mature
into potent immunostimulatory dendritic cells in vitro.J. Exp. Med. 161 :526.
22. Schuler, G., N . Romani, and R. M. Steinman. 1985. A comparison of murine
epidermal Langerhans' cells with spleen dendritic cells.J. Invest. Dermatol. 85:99s.
23. Inaba, K., G. Schuler, M. D. Witmer, J. Valinsky, B. Atassi, and R. M. Steinman.
1986. Immunologic properties of purified epidermal Langerhans' cells. Distinct
requirements for stimulation of unprimed and sensitized T lymphocytes. J. Exp. Med.
164:605.
24. Nathan, C . F., G. Kaplan, W . R. Levis, A. Nusrat, M. D. Witmer, S. A. Sherwin, C.
K. Job, C. R . Horowitz, R. M. Steinman, and Z. A. Cohn. 1986. Local and systemic
effects of intradermal recombinant interferon-7 in patients with lepromatous leprosy.
N. Engl. J. Med. 315:6.
25. Kaplan, G., A. Nusrat, E. N . Sarno, C. K. Job, J. McElrath, J. A. Porto, C. F. Nathan,
and Z. A. Cohn. 1987 . Cellular responses to the intradermal injection ofrecombinant
human -y-interferon in lepromatous leprosy patients. Am. J. Pathol. 128:255.
26. Deuel, T. F., P. S . Keim, M. Farmer, and R. L. Heinrikson. 1977. Amino acid
sequence of human platelet factor 4. Proc. Natl. Acad. Sci. USA. 74:2256 .
27. Castor, W ., J. W. Miller, and D. A. Walz . 1983 . Structural and biological character-
istics of connective tissue activating peptide (CTAP-III), a major human platelet-
derived growth factor. Proc. Natl. Acad. Sci. USA. 80:765.
28. Sugano, S., M . Y. Stoekle, and H. Hanafusa. 1987. Transformation by Rous sarcoma
virus induces a novel gene with homology to a mitogenic platelet protein. Cell.
49:321 .